Evotec SE EVO
1.32 USD -0.13 (-8.97%)
Regular-session close
1.34 +0.02 +1.52%
After hours · Nov 20, 5:47 PM ET
1.32 Day range 1.38
1.32 52-week range 3.87
- YTD
- -57.14%
- 1 year
- -54.48%
Benzinga news
benzinga.com Evotec, Bristol Myers Squibb Protein Degradation Partnership Receives Second FDA Investigational New Drug Acceptance For CELMoD Candidate, Phase 1 Expected In 2027 FDA clearance expands partnered molecular glue pipelineAchievement underscores productivity of the collaboration in molecular glue discovery and potential to address patient populations with high…
benzinga.com Evotec Lands $2.9M Gates Foundation Grant Giving Global Health Researchers Continued Access To Stem Cell Platform For Early Drug Safety Assessment New three-year grant from the Gates Foundation extends a 2023 project to help global health researchers predict potential fetal development risks posed by novel drug candidatesEvotec's human stem…
benzinga.com HC Wainwright & Co. Maintains Buy on Evotec, Raises Price Target to $5 HC Wainwright & Co. analyst Swayampakula Ramakanth maintains Evotec (NASDAQ:EVO) with a Buy and raises the price target from $4 to $5.
benzinga.com Evotec Affirms FY2026 Sales Guidance of $656.004M-$702.039M vs $681.980M Est Evotec (NASDAQ:EVO) affirms FY2026 sales outlook from $656.004 million-$702.039 million to $656.004 million-$702.039 million vs $681.980 million estimate.
benzinga.com Evotec Q3 EPS €(0.15) Misses €(0.14) Estimate Evotec (NASDAQ:EVO) reported quarterly losses of €(0.15) per share which missed the analyst consensus estimate of €(0.14) by 7.14 percent. This is a 40 percent increase over losses of €(0.25) per…
benzinga.com Evotec Q3 Sales €164.926M Miss €167.080M Estimate Evotec (NASDAQ:EVO) reported quarterly sales of €164.926 million which missed the analyst consensus estimate of €167.080 million by 1.29 percent. This is a 0.63 percent increase over sales of…
